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The v-fgr oncogene encodes a chimeric oncoprotein composed of feline sarcoma virus (FeSV)-derived gag and cellular-
derived actin and c-Fgr sequences. v-Fgr is myristoylated and membrane bound, two criteria which must be met for src
kinases to induce cellular transformation. Although inhibition of myristoylation resulted in a decreased ability of v-Fgr to
sediment with membranes from an NIH-3T3 P100 fraction, deletion of the gag domain caused nearly all of the protein to
remain unbound and cytosolic. Systematic deletions within gag indicate that while amino acids 3 through 9 are critical
determinants of myristoylation and/or define a domain which directs membrane localization, these residues cooperate with
additional gag sequences when anchoring the protein to the plasma membrane. Furthermore, nonmyristoylated and/or
cytoplasmic variants of v-Fgr failed to induce anchorage-independent growth of NIH-3T3 cells, indicating that proper
subcellular localization of v-Fgr is a key factor in its ability to induce transformation. © 1998 Academic Press
INTRODUCTION
The v-fgr oncogene was originally isolated from the
acutely transforming Gardner-Rasheed feline sarcoma
virus (GR-FeSV), and it encodes a protein of 664 amino
acids with an expected molecular weight of 70 kDa
(Naharro et al., 1984; reviewed in Rasheed, 1988). The
N-terminal end of the protein (amino acid residues
1–118) is homologous to the p15 FeLV gag matrix protein,
while the remainder of the protein is composed of trans-
duced actin (amino acids 141–268) and c-fgr (amino acid
residues 269–658) cellular-derived sequences (Naharro
et al., 1984). The c-fgr homologous sequences mostly
comprise the SH2 and kinase domains. A regulatory
tyrosine residue (Y553, analogous to tyrosine 416 of Src)
enables v-Fgr to undergo autophosphorylation. However,
the C-terminal negative regulatory tyrosine (analogous to
tyrosine 527 of Src) has been deleted during transduc-
tion. The absence of an analogous Y527-like residue in
v-Fgr is responsible for its enhanced catalytic activity in
vitro and is at least partly responsible for its transforming
ability.
v-Fgr is myristoylated (Schultz and Oroszlan, 1984) and
is associated with the plasma membrane in transformed
cells (Manger et al., 1986). It has been demonstrated that
many viral gag proteins as well as members of the src
family of tyrosine kinases are myristoylated and that this
form of protein modification was necessary for proper
protein function, including viral assembly at the mem-
brane, subcellular localization, and transformation (re-
viewed in Resh, 1996). Myristoylation alone is insufficient
to direct membrane localization, and as a result, several
myristoylated proteins, including src kinases, use a ‘‘two-
component’’ membrane localization signal. The first com-
ponent, myristic acid, is required but is not sufficient for
membrane localization as its interaction is merely hydro-
phobic. The second component, a single or cluster of
negatively charged, basic amino acids (Kaplan et al.,
1988; Silverman and Resh, 1992; Silverman et al., 1992),
provides additional electrostatic interactions at the pos-
itively charged lipid bilayer head groups (Sigal et al.,
1994). Similar motifs (i.e., myristoylation plus a second
cluster of basic amino acids) are used by mammalian
(Platt and Haffar, 1994; Spearman et al., 1994; Zhou et al.,
1994; Zhou and Resh, 1996) and RSV retroviral gag pro-
teins (Parent et al., 1996; Verderame et al., 1996) during
assembly at the plasma membrane.
Because the structure of the v-Fgr protein is unique
among the src kinases in the sense that it is chimeric,
having viral-derived gag sequences at the N terminus
and cellular-derived actin and c-fgr sequences at the C
terminus, it was of interest to determine whether the
sequences that anchor v-Fgr to the plasma membrane
are similar to those that dictate cytoplasic membrane
binding of related gag proteins and/or Src family mem-
bers. It was also of interest to examine whether actin
sequences present in the v-Fgr protein play a role in
membrane localization of the protein. Our results indi-
cate that while the N-terminal 10 amino acids are critical
for myristoylation and/or define a plasma membrane
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binding motif, they are insufficient to target the protein to
the membrane. Instead, this region cooperates with ad-
ditional sequences in the gag domain when directing
membrane localization. Although nonmyristoylated v-Fgr
mutants failed to induce anchorage-independent growth
of NIH-3T3 cells, restoration of myristoylation to a gag
deletion mutant (which contained the actin sequences)
failed to restore transformation ability. These results fur-
ther suggest that two signals (i.e., myristate and gag
sequences) direct v-Fgr subcellular localization and that
actin sequences present in the v-Fgr protein by them-
selves cannot substitute for those of gag.
RESULTS
The myristic acid attachment site, glycine-2, is
required to target v-Fgr to the plasma membrane
To determine the role of myristoylation in anchoring
v-Fgr to the plasma membrane, two v-fgr mutants were
generated which lack a consensus myristoylation signal
(Fig. 1). One mutant, termed D2-9, lacks the glycine-2
myristate moiety attachment site as well as the next
seven amino acid residues; amino acids located in the
identical position are essential for efficient myristoylation
of v-Src (Cross et al., 1984; Pellman et al., 1985a,b; Kaplan
et al., 1988). The second mutant, termed G2A, contains
only a glycine-to-alanine amino acid substitution at the
second position glycine residue and destroys the myris-
tic acid attachment site. Both mutants as well as wild-
type v-fgr were subcloned into pBluescript KS, subjected
to T7-primed TNT coupled in vitro transcription and
translation, and assayed for their ability to bind to the
plasma-membrane-enriched P100 fraction of fraction-
ated NIH-3T3 cells as described under Materials and
Methods. It has been previously demonstrated that re-
ticulocyte lysates contain sufficient amounts of N-
myristoyl transferase, the enzyme that catalyzes the
transfer of myristic acid to glycine-2 (Deichaite et al.,
1988). Therefore, to verify the myristoylation status of the
wild-type and mutant Fgr proteins, we performed in vitro
translation reactions in the presence of 3H-myristic acid
and subjected the labeled proteins to SDS–PAGE (Fig. 2).
As can be seen in lanes 1–3, the wild-type v-Fgr protein
was efficiently myristoylated, while the D2–9 and G2A
mutants failed to undergo any myristoylation, confirming
that glycine at position 2 is important for myristoylation of
the Fgr protein. We next performed in vitro transcription/
translation reactions in the presence of 35S-Translabel
and assayed the in vitro translated proteins for their
ability to bind to the plasma-membrane-enriched P100
fraction of fractionated NIH-3T3 cells. In this assay
(Resh, 1989), the amount of in vitro translated protein that
is co-pelleted with cytoplasmic membranes from the
P100 fraction under ultracentrifugation at 150,000 g rep-
resents the percentage of protein that is associated with
the plasma membrane. As a negative control, each in
vitro translated protein was also ultracentrifuged simul-
taneously with the experimental samples in the absence
of any P100 fractionated protein to established its back-
ground aggregation and/or binding level. A representa-
tive gel is shown in Fig. 3A.
Approximately 65% of the wild-type v-Fgr in vitro trans-
lated protein, after ultracentrifugation at 150,000 g, re-
mained associated with the pelleted plasma-membrane-
FIG. 1 Schematic representation of wild-type and mutant forms of
v-Fgr used in in vitro membrane association assays.
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enriched fraction (Figs. 3A and 3B). This value is consis-
tent with the results obtained by Silverman and Resh
(1992) for the related myristoylated v-Src viral oncopro-
tein. Because previous results had also demonstrated
that nonmyristoylated forms of v-Src were unable to as-
sociate with the plasma membrane (Cross et al., 1985;
Garber et al., 1985; Kamps et al., 1985), it was of interest
to determine whether our above myristoylation-defective
mutants lost their ability to sediment with the P100 frac-
tion under identical experimental conditions. As seen in
Fig. 3B, roughly 36 and 42% of the D2–9 and G2A mutant
proteins associated with the pelleted fraction, respec-
tively. These results, which are consistent with those
reported by others for related proteins with similar mu-
tations (Cross et al., 1985; Garber et al., 1985; Kamps et
al., 1985; Calothy et al., 1987), demonstrate that mutant
forms of v-Fgr that do not encode a myristoylation signal
have a decreased binding affinity for plasma membranes
isolated from NIH-3T3 cells. Because neither mutant is
myristoylated in vitro (Fig. 2, lanes 2 and 3), these results
also suggest that myristoylation is important to anchor
v-Fgr to the plasma membrane.
v-Fgr requires an intact N terminus for attachment to
the plasma membrane
Several studies have shown that the amino acids
that are immediately downstream of the penultimate
glycine are able to act as a myristoylation signal for
v-Src (Cross et al., 1984; Pellman et al., 1985a,b;
Kaplan et al., 1990); and in fact, many proteins be-
longing to the Src family require only the first 10–14
amino acids for efficient myristoylation and subcellular
localization to the inner leaflet of the plasma mem-
brane (Kaplan et al., 1988). We therefore generated an
N-terminal mutant (D3–9) (Fig. 1) in which the glycine-2
myristate attachment site has been left intact and only
amino acids 3–9 have been deleted and determined
whether it binds to the plasma-membrane-enriched
P100 fraction. As seen in Fig. 3B, roughly 36% of the
D3–9 protein pelleted with the P100 plasma membrane
fraction after ultracentrifugation. This value is remark-
ably similar to that which was obtained for the D2–9
mutant, despite the fact that the D3–9 mutant is myr-
istoylated at low levels (Fig. 2, lane 4). Taken together,
these results suggest that the first nine amino acids of
v-Fgr are required for efficient myristoylation and/or
define a plasma membrane binding domain.
FIG. 3. Membrane association of in vitro translated wild-type and
mutant v-Fgr proteins. (A) Duplicate 5-ml aliquots of TNT coupled in
vitro transcribed-translated wild-type (lanes 1–6) or D2–9 (lanes
7–12) v-Fgr protein were incubated with 15 mg (in a volume of 30ml)
of a P100 plasma membrane fraction derived from NIH-3T3 cells
(lanes 1–4 and 7–10) or NTE buffer alone (lanes 5–6 and 11–12) at
20°C for 30 min. Binding reactions were ultracentrifuged for 30 min
at 4°C at 150,000 g, and the pellet (representing the percentage of
plasma membrane-bound protein) and the supernatant (represent-
ing the percentage of cytoplasmic protein) were resolved by SDS–
PAGE. (B) Aliquots (5 ml) of TNT coupled in vitro transcribed-trans-
lated v-Fgr protein were incubated with 15 mg (in a volume of 30ml)
of a P100 plasma membrane fraction derived from NIH-3T3 cells
(1Mbs) or NTE buffer (2Mbs) at 20°C for 30 min. Binding reactions
were ultracentrifuged for 30 min at 4°C at 150,000 g. The pellet and
supernatant were analyzed by SDS–PAGE and quantitated using
MacBas software in conjunction with the Fuji phosphorimager. Each
bar represents the average plus the standard deviation of six sep-
arate experiments.
FIG. 2. In vitro myristoylation of v-Fgr proteins. Wild-type and the
indicated v-fgr mutant cDNAs were subcloned into the pBluescript
KS vector and subjected to T7-primed coupled in vitro transcription/
translation (TNT) reactions supplemented with 3H-myristic acid
(top). The identical cDNAs were also transcribed/translated in the
presence of 35S-protein labeling mix to control for translation effi-
ciency (bottom). The entire reaction (for 3H-labeled proteins) or a
5-ml aliquot (for 35S-labeled proteins) was resolved by 10% SDS–
PAGE, and the resulting proteins were visualized by phosphorim-
ager analysis (for 3H-labeled proteins) or autoradiography (for 35S-
labeled proteins).
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The gag domain confers additional plasma membrane
binding ability to v-Fgr
Many myristoylated gag proteins use other sequences
in addition to the myristate attachment site to anchor
themselves to the plasma membrane. For example, other
groups (Platt and Haffar, 1994; Zhou and Resh, 1996)
have determined that both N- and C-terminal sequences
in the HIV Type 1 Pr55gag protein, in conjunction with the
myristate moiety, are required to target gag precursor
proteins to the plasma membrane. In addition, v-Src
contains multiple membrane attachment sites which are
scattered throughout the protein (Kaplan et al., 1990). To
determine whether the viral gag sequences that are
present in v-Fgr, but not in related proteins such as v-Src
and c-Fgr, contributed to its ability to associate with the
plasma membrane, we generated an additional mutant,
termed D2–116 (DGag), which deletes all of the residues
that comprise the gag domain with the exception of the
initiator methionine (Fig. 1).
As can be seen in Fig. 4, deletion of the gag se-
quences in the D2–116 mutant rendered v-Fgr unable to
associate with the plasma membrane in our assays,
allowing only 20% of the protein to pellet with the mem-
brane fraction. This value is similar to that obtained for a
nonrelated nuclear viral oncoprotein protein, v-myb
(which is soluble), and suggests that this value is at or is
barely above background in this assay (data not shown).
To determine whether there is a particular region within
the v-Fgr gag domain that mediates binding to the
plasma membrane in addition to the myristate moiety, a
series of six systematic in-frame deletion mutants, each
deleting no more than 20 amino acids of gag (Fig. 1) was
constructed in the context of the G2A amino acid substi-
tution and subjected to in vitro membrane association
assays. As seen in Fig. 4, only three mutants, G2AD19–
38, G2AD79–98, and G2AD99–116, exhibited a lower per-
centage (29%) of protein associating with the plasma
membrane, although overall none of the mutants mark-
edly lost its ability to sediment with the membrane frac-
tion when compared with DGag (20%). While it is possi-
ble that deletion of the entire gag domain resulted in a
gross conformational distortion of the protein, it is also
feasible that multiple regions within v-Fgr Gag, such as
HIV Pr55gag and v-Src, cooperate with the myristic acid
chain to anchor v-Fgr to the plasma membrane.
To confirm the hypothesis that in addition to myristoyl-
ation downstream gag sequences are required for mem-
brane binding, we generated two variants of v-Fgr DGag
that encode myristoylation signals (Fig. 1). The first mutant,
D10–116, deletes the entire Gag domain with the exception
of the first nine amino acids that contain a myristate attach-
ment site and the sequences which presumably specify
this modification. The second mutant, D3–116, contains
only the glycine-2 residue to which myristic acid is attached
but does not encode amino acids 3–9, which appear to
direct membrane association and/or myristoylation. Figure
5 shows that the D3–116 mutant behaved similar to D2–116
(DGag) despite the presence of a myristoylation signal (21%
vs 20% binding, respectively). However, despite the fact that
more than twice the amount (roughly 46%) of the D10–116
mutant protein was able to sediment with the membrane
fraction, the addition of amino acids 3–9 was not sufficient
to restore binding levels to that of the wild-type protein.
FIG. 5. In vitro membrane association of in vitro translated v-Fgr
mutants D10–116 and D3–116. Experiments were performed as de-
scribed in Fig. 3. The binding of D2–116 (DGag) is indicated as a
control.
FIG. 4. In vitro membrane association of in vitro translated D2–116
(DGag) and systematic Gag deletion mutants. Experiments were per-
formed as described in Fig. 3. v-Fgr G2A is indicated as a control.
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Interestingly, both mutants were myristoylated in vitro (Fig.
2, lanes 6 and 7), although the extent to which the D3–116
protein was modified was considerably less than that of
D10–116. These results are consistent with our previous
finding that the N-terminal nine amino acids of Gag define
a v-Fgr membrane attachment site and/or influence myris-
toylation. However, neither this domain nor myristoylation is
sufficient to anchor v-Fgr to the plasma membrane at wild-
type levels, indicating that v-Fgr contains multiple sites that
influence its subcellular localization.
To assess whether a minimal region of gag is ade-
quate to facilitate membrane localization of the protein,
we constructed a deletion mutant that contained amino
acids 1–78 of Gag (D79–116) with and without glycine at
position 2 (Fig. 1). When these constructs were tested for
their ability to associate with cell membranes in vitro
(Fig. 6), we observed that this deletion mutant, in the
absence of glycine-to-alanine mutation at position 2,
exhibited membrane association that was equal to that
of the wild-type protein. On the other hand, substitution
of alanine at position 2 and deletion of amino acid se-
quences 79–116 resulted in a substantial loss in the
ability of this mutant protein to associate with cell mem-
branes. These results further confirm the earlier obser-
vation that the gag sequences present in the v-Fgr pro-
tein have multiple domains that cooperate with myristic
acid in anchoring the protein to the cell membrane.
Myristoylation of v-Fgr is required to induce cellular
transformation
A positive correlation exists between the myristoyl-
ation status and subcellular localization of v-Src and its
ability to induce morphological transformation in vivo
(Cross et al., 1984; Garber et al., 1985; Kamps et al.,
1985a; Pellman et al., 1985): wild-type v-Src and mutants
that retain their membrane binding potential are able to
transform, whereas nonmyristoylated, cytoplasmic vari-
ants lose this ability. Because NIH-3T3 cells that overex-
press v-fgr form foci and are anchorage independent
(Miyoshi et al., 1989; Sugita et al., 1989; Sartor et al.,
1992), we were interested in whether v-Fgr, despite its
unique structure and usage of different membrane an-
choring sequences, shared this property with v-Src. We
therefore subcloned the wild-type and myristoylation
negative D2–9 and G2A mutant v-fgr cDNAs into the
pMV7 retroviral vector (Kirchmeier et al., 1988) and intro-
duced these plasmids into actively proliferating NIH-3T3
cells by a standard calcium phosphate method (Graham
and van der Eb, 1973). Three individual clonal cell lines
representing each construct were selected using G418
and assayed for their ability to form anchorage-indepen-
dent colonies in semisolid medium and to undergo au-
tophosphorylation. One representative cell line for each
construct is shown and discussed here since all clones
for each construct displayed identical protein profiles
and behaved identically in our assays.
While NIH-3T3 cells expressing wild-type v-fgr readily
formed colonies within 1 week after plating in soft agar
(Fig. 7A), the D2–9 and G2A myristoylation mutant-
expressing cells (Figs. 7B and 7C) and cells transfected
with the parental vector (Fig. 7H) failed to do so even
after 4 weeks in culture. To ensure that the mutant
proteins retained their catalytic activity, each protein was
subjected to in vitro kinase assays. Figure 8A shows that
the wild-type, D2–9, and G2A v-Fgr proteins underwent
autophosphorylation at similar levels (lanes 1–3) and
exhibited approximately equal levels of protein expres-
sion (Fig. 8B). These results suggest that decreased
catalytic activity did not account for the lack of transfor-
mation.
Myristoylation of v-Fgr is required but not sufficient
to induce cellular transformation
Although most v-Src variants fall into one of the above-
mentioned membrane association/transformation cate-
gories, there are several myristoylated mutants that fail
to induce transformation as a result of aberrant subcel-
lular localization (Garber et al., 1985). Interestingly, two of
our mutants, D3–9 and D3–116, encode myristoylation
attachment sites and are weakly myristoylated in vitro
(Fig. 2) but fail to associate with the plasma membrane;
a third mutant, D10–116, while unable to associate with
the plasma membrane at wild-type levels, did exhibit
increased levels of membrane binding in our assays and
was mryistoylated at nearly wild-type levels in vitro (Fig.
2). These results suggest that myristoylation is insuffi-
cient to anchor v-Fgr to the plasma membrane and indi-
FIG. 6. In vitro membrane association of in vitro translated v-Fgr
mutants D79–116 and G2aD79–116. Experiments were performed as
described in Fig. 3.
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cate that the N-terminal nine amino acids as well as one
or more C-terminal Gag domains cooperate with the
myristic acid chain to influence subcellular localization.
To test the hypothesis that subcellular localization of
v-Fgr, in addition to myristoylation, influences its trans-
forming potential, these mutants, including D2–116
(DGag) as an additional negative control, were sub-
cloned into pMV7 and assayed for their ability to induce
anchorage-independent growth of NIH-3T3 cells.
Figure 7 (D–G) shows that, as expected, neither mu-
tant was able to induce colony formation in soft agar,
despite the fact that each of these mutants, with the
exception of D2–116 (DGag), are myristoylated to some
extent in vitro (Figure 2). As seen in Fig. 8, all mutants
were autophosphorylated, indicating that an absence of
kinase activity could not account for their nontransform-
ing phenotype. The fact that the D10–116 mutant is myr-
istoylated at nearly wild-type levels but failed to induce
anchorage-independent growth further supports previ-
ous data which suggest that myristoylation alone is not
sufficient to influence membrane localization and trans-
formation and that additional sequences in the gag do-
main influence these processes.
DISCUSSION
The v-Fgr transforming oncoprotein has a tripartite
structure. Its N terminus is composed of viral-derived p15
gag and cellular-derived actin sequences, while its C-
terminal half is homologous to the SH2 and kinase do-
mains of its cellular homolog, c-fgr, a member of the src
tyrosine kinases (Naharro et al., 1984). Like all mamma-
lian retroviral gag proteins, the transduced FeSV p15
(matrix) sequences encode a myristoylation signal at
glycine-2 (Schultz and Orloszan, 1984), which directs
association with the intracellular face of the plasma
membrane and subsequently facilitates gag-mediated
retroviral particle assembly. Myristoylation is also a crit-
ical determinant in the regulation of src kinases, whose
proper subcellular localization determines their interac-
tions with substrates and regulatory proteins (reviewed
in Resh, 1996). As v-Fgr is membrane associated (Man-
ger et al., 1986) but is encoded by sequences that are
FeSV and fgr derived, it was of interest to determine the
relative contributions of both sequences in directing
membrane localization.
As expected from previous studies with v-Src (Cross et
al., 1984, 1985; Garber et al., 1985; Kamps et al., 1985;
Pellman et al., 1985a; Calothy et al., 1987), inhibition of
v-Fgr myristoylation caused by the substitution of alanine
for glycine-2 resulted in the majority of the protein
(roughly 58%) remaining cytosolic and the destruction of
its transforming ability (Fig. 3B and 7). Interestingly,
greater amounts of protein remained cytosolic (approxi-
mately 64%) when amino acids 2–9 were deleted (D2–9),
suggesting that additional amino acids may influence
subcellular localization and/or myristoylation. In accor-
dance, these studies also show that a second deletion
mutant that retains the myristic acid attachment site but
deletes residues 3–9 (D3–9) fails to associate with the
plasma membrane in a nearly identical manner to D2–9
(Fig. 3B) despite the fact that it is weakly myristoylated
(Fig. 2). Although it is possible that N-myristoyl trans-
ferase (NMT) fails to recognize the D3–9 mutant, which
has a serine residue penultimate to glycine-2, studies
with octapeptides indicate that this is not the case
(Towler et al., 1987). Instead, these results support earlier
FIG. 7. Growth of NIH-3T3 cells that overexpress wild-type and mutant v-fgr in semisolid medium. Cells (1 3 105) derived from three individual clonal
cell lines representing wild-type (A), D2–9 (B), G2A (C), D3–9 (D), D2–9-116 (DGag; E), D10–116 (F), D3–116 (G), and pMV7 (H) transfected NIH-3T3 cells
were plated in duplicate in DMEM supplemented with 5% calf serum and 0.4% noble agar. Anchorage-independent colonies were scored 2 weeks
after plating.
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findings for v-Src (Cross et al., 1984, 1985; Garber et al.,
1985; Pellman et al., 1985a; Resh, 1989) that demon-
strated that the first 10–14 amino acids, especially ly-
sine-7, are sufficient for membrane localization and crit-
ical for myristoylation (Kaplan et al., 1988, 1990). It has
been hypothesized that basic residues, such as lysine,
are required to provide electrostatic interactions in ad-
dition to the hydrophobic interaction that is provided by
myristate at the membrane (Silverman and Resh, 1992;
Sigal et al., 1994). Although v-Fgr does not contain any
basic amino acid residues in this region, it does contain
several nonpolar residues (i.e., leucine, isoleucine, and
proline), which may interact with the membrane and
strengthen the attachment that is provided by myristic
acid in the N-terminal region.
This interpretation, however, is complicated by the
fact that deletion of the entire Gag domain (D2–116)
completely destroyed the ability of v-Fgr to bind to the
plasma membrane. Like v-Src, mammalian gag pro-
teins use additional sequences of basic amino acids
in conjunction with myristoylation for subcellular local-
ization. In HIV Type 1 for instance, one sequence is
located in the first 31 amino acids of the matrix protein
(Spearman et al., 1994; Zhou et al., 1994; Zhou and
Resh, 1996), while a second is located further down-
stream in the C terminus of the gag precursor (Platt
and Haffar, 1994). A similar, but much larger domain is
used by RSV, whose gag protein is not myristoylated
(Parent et al., 1996; Verderame et al., 1996). Additional
systematic deletions within the v-Fgr gag domain,
however, failed to accurately localize a particular re-
gion whose removal could mimic that of the entire gag
portion of the protein. This is somewhat surprising
since previous studies had revealed that deletion of
the last third of gag inhibited transformation (Miyoshi
et al., 1989). Slightly weaker binding, however, was
observed using constructs that had deletions in the
region encompassing amino acids 79–116 (29% for
mutations which encompassed this region vs 36% for
the others), but this was only observed in a nonmyr-
istoylated protein (Fig. 6). It is of interest to note that
the last one-third of gag is rich in proline residues.
Recent studies have shown that proline-rich regions,
in particular sequences that conform to the sequence
PXXP, can associate with SH3 domain-containing pro-
teins (Ren et al., 1993). It is therefore possible that
these sequences interact with and may even phos-
phorylate proteins that induce transformation and that
the inhibition of transformation has little to do with the
ability of these sequences to directly influence mem-
brane binding.
Even in the absence of a defined region within gag
that directs subcellular localization, the D3–116 and D10–
116 deletion mutants support the notion that a second
domain, in conjunction with the first nine amino acids,
cooperates with myristate. Although the D3–116 protein
is myristoylated, albeit to a lesser extent, it has nearly the
identical affinity for the plasma membrane as nonmyris-
toylated D2–116 (Fig. 5). However, when the first nine
amino acids were left intact in D10–116, more than twice
the amount of protein sedimented with the plasma mem-
brane fraction (46% vs 21%), and the protein was myris-
toylated at levels that are nearly equal to that of wild type
(Figs. 2 and 5). This percentage, however, was not equal
to that of wild-type v-Fgr, which exhibited 65% membrane
binding. These results argue that while the first nine
amino acids are important in determining whether v-Fgr
is myristoylated and/or membrane bound, as a group
they are insufficient to direct subcellular localization.
Subcellular localization is often a good predictor of
cellular transformation. As previously stated, mutations
which redirect v-Src to the cytosol abolish its transform-
ing ability. To assess whether v-Fgr mutants exhibit sim-
ilar properties, we expressed these mutant proteins in
NIH-3T3 cells and determined their ability to cofraction-
ate with cell membranes and whether this property cor-
related with their transforming activity. We find that the in
FIG. 8. Expression of v-Fgr proteins in NIH-3T3 cells. (A) NIH-3T3
cells transfected with wild-type (wt) and indicated mutant pMV7-vfgr
constructs were selected in the presence of G418. Whole cell lysate (1
mg) in kinase buffer was subjected to immunoprecipitation analysis
using a Fgr-specific antibody. Immunoprecipitates were washed three
times in kinase buffer and once in kinase reaction buffer (see Materials
and Methods). In vitro kinase reactions were performed at 30°C for 20
min in 40 ml kinase reaction buffer supplemented with 100 mM Na2VO4,
20 mM ATP, and 5 mCi [32P]g ATP. Proteins were resolved using 10%
SDS–PAGE, and the resulting gel was subjected to autoradiography.
Autophosphorylated proteins are indicated by the arrows. (B) Whole
cell lysate (1 mg) in RIPA buffer was immunoprecipitated using a Fgr
specific antiserum (Santa Cruz), resolved by SDS–PAGE, and subjected
to Western blot analysis using the same antiserum (see Materials and
Methods). Fgr protein are indicated by the arrows.
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vivo membrane phenotypes for these mutants are very
similar to those we described in vitro (data not shown). In
addition, none of the mutants that were defective in
membrane association were able to induce anchorage-
independent growth in semisolid medium, indicating that
the gag domain and myristoylation are required for this
phenomenon (Fig. 7). As there are some mutants of v-src
that are weakly transforming and induce a transformed
morphology that is different from those transformed by
wild-type v-src, it would have been interesting to deter-
mine whether any of the v-fgr mutants used in this assay
had a similar effect. Unfortunately, numerous attempts to
induce focus formation with these mutants in NIH-3T3
cells failed. Although most fgr mutants that fail to induce
focus formation also fail to induce anchorage-indepen-
dent growth (Sartor et al., 1992), the ability of any of the
mutants, especially D10–116, which binds at a level that
is between that of the wild type and D2–116 (DGag), to
induce an altered cellular morphology that is indicative of
a weakly transformed phenotype cannot be ruled out.
We also cannot negate the involvement of residues
within the v-Fgr SH2 domain in influencing membrane
localization and transformation. Previous studies have
suggested that amino acids within the v-Src and v-Fgr
SH2 domains are required for membrane binding and
are critical for the induction of a transformed phenotype
(Sugita et al., 1989; Kaplan et al., 1990). Deletion of the
SH2 domain also prevents Src from associating with the
cytoskeleton subsequent to membrane localization and
from interacting with substrates that are localized to this
region (Okamura and Resh, 1994). Curiously, deletion of
the v-Fgr actin domain does not alter its association with
the cytoskeleton or its transforming ability (Miyoshi et al.,
1989; Sugita et al., 1989). Our membrane localization
studies (data not shown) suggest that myristoylation
does not mask previous actin deletions and are, there-
fore, in accordance with these findings. The reason as to
why FeSV would acquire these sequences during trans-
duction still remains unknown. It is possible that the
presence of actin sequences permits greater stability
and/or increased translation efficiency of the protein.
However, the fusion of nontransforming c-fgr sequences
with the gag matrix protein appears to have been very
beneficial for the virus and may partly reveal why v-fgr
and not c-fgr transforms cells.
MATERIALS AND METHODS
Cell lines
NIH-3T3 cells were maintained in Dulbecco’s modified
Eagle medium (DMEM) (Life Technologies) supple-
mented with 10% calf serum (Life Technologies) and
penicillin-streptomycin at 37°C under humidified condi-
tions and 8% CO2.
Generation of Fgr-specific antiserum
Two GST (glutatione-S-transferase) fusion proteins
(Pharmacia), which separately encoded amino acids
125–182 (the c-Fgr SH3 domain and its immediate 39
unique region) and amino acids 183–266 (the c-Fgr SH2
domain and its immediate 39 unique region), and a MBP
(maltose binding protein) fusion protein (New England
Biolabs) encoding amino acids 267–516 (the c-Fgr ty-
rosine kinase domain) were purified according to the
manufacturers’ protocols. All proteins were combined
and used as a single antigen to generate a rabbit poly-
clonal antiserum.
In vitro kinase assays
In vitro kinase reactions were performed as previously
described (Hibi et al., 1993). Cell pellets were lysed in
kinase lysis buffer (25 mM HEPES, pH 7.5; 0.1% Triton
X-100; 300 mM NaCl; 20 mM b-glycerophosphate; 1.5
mM MgCl2] 0.2 mM EDTA; 2.0 mM dithiothreitol (DTT); 0.2
mM Na2VO4; 2 mg/ml leupeptin; 4 mg/ml aprotinin; and 4
mg/ml pepstatin A) and clarified by microcentrifugation,
and the protein concentration was determined using
BioRad reagent (BioRad). Total cell lysate (1 mg) was
immunoprecipitated using the Fgr-specific antibody de-
scribed above for 2 h at 4°C. The resulting immune
complexes were precipitated using 50 ml of protein A
sepharose (50% slurry), and the beads were washed
three times in lysis buffer and once in kinase reaction
buffer (20 mM HEPES, pH 7.5; 20 mM MgCl2; 20 mM
b-glycerophosphate; 20 mM p-nitrophenylphosphate; 0.1
mM Na2VO4; and 2 mM DTT). Kinase reaction buffer (40
ml) supplemented with 20 mM ATP and 5 mCi of
g-[32P]ATP was added to each sample and incubated for
20 min at 30°C. In vitro phosphorylated proteins were
separated by 10% SDS–PAGE according to Lammeli
(1970). The resulting gel was fixed overnight in fixative
solution (10% glacial acetic acid and 30 methanol) and
dried, and the phosphorylated proteins were visualized
by autoradiography.
Immunoprecipitation and Western blot analysis
Cell pellets were lysed in RIPA buffer (150 mM NaCl;
50 mM Tris-Cl, pH 7.5; 1% Nonidet-P40; 0.1% sodium
deoxycholate; 0.1% SDS; 1 mM EDTA; 1 mM EGTA; 1 mM
PMSF; 4 mg/ml aprotinin; 4 mg/ml leupeptin; and 4 mg/ml
pepstatin A) and incubated on ice for 30 min. Clarified
lysate (1 mg) was immunoprecipitated using a Fgr-spe-
cific antiserum (Santa Cruz) for 2 h at 4°C. The resulting
immune complexes were precipitated using 50 ml protein
A sepharose (50% slurry), and the beads were washed
once in RIPA buffer, once in 1/10 detergent buffer (150
mM NaCl; 50 mM Tris-Cl, pH 7.5; 0.1% Nonidet-P40; 0.01%
sodium deoxycholate; 0.01% SDS; 1 mM EDTA; and 1 mM
EGTA), and once in PBS. All proteins were resolved by
8 BAKER, COSENZA, AND REDDY
SDS–PAGE according to Lammeli (1970) and transferred
to nitrocellulose. The membrane was blocked at room
temperature for 30 min in 5% nonfat milk in T-TBS (150
mM NaCl; 20 mM Tris-Cl, pH 7.5; and 0.05% Tween 20)
and then incubated for 1 h in TBS-T supplemented with
Fgr antiserum (described above). After three washes in
TBS-T, the filter was incubated with a horseradish per-
oxidase-conjugated secondary antibody (Amersham)
and subsequently washed according to the instructions
of the manufacturer. Protein-antibody complexes were
visualized using enhanced chemiluminescence (Amer-
sham).
Construction of v-fgr deletion and point mutants
v-fgr mutants were created using oligonucleotide-
directed mutagenesis (reviewed in Myers et al., 1989)
using the following primers. The structure and integrity of
each mutant was confirmed by Sanger dideoxy se-
quence analysis. The positions of each oligonucleotide,
numbered 1–4 for each construct, are provided below
with the sequence of the internal (with sequences that
are mutated, introduced or are 59 to the deletion in
boldface) and external (with cloning restriction sites un-
derlined) oligonucleotides used to make each mutation
within the v-fgr cDNA are indicated below; the template
DNA, unless otherwise indicated, is pBluescript v-fgr
(wild-type): D2–9, (1) 59-ATTACGACTCACTATAG-39 (T7
primer, SacI restriction site used for cloning is immedi-
ately downstream of this sequence and is immeadiately
upestream of the v-fgr cDNA), (2) 59-AAT GCA GAA ACC
GTC ATG CTC ACC CTT GAT CAC TGG-39, (3) 59-CCA
GTG ATC AAG GGT GAG CAT GAC GGT TTC TGC
ATT-39, (4) 59-ATT TCT TTT TCC GGA CCT GGA-39; G2A,
(1) identical to primer 1 used to generate D2–9, (2) 59-
GGA ACC GTC ATG GCC CAA ACT ATA ACT-39, (3)
59-AGT TAT AGT TTG GGC CAT GAC GGT TTC-39, (4)
identical to primer 4 used to generate D2–9; D3–9, (1)
identical to primer 1 used to generate D2–9, (2) 59-AAT
GCA GAA ACC GTC ATG GGC CTC ACC CTT GAT CAC
TGG TCT-39, (3) 59-AGA CCA GTG ATC AAG GGT GAG
GCC CAT GAC GGT TTC TGC AAT-39, (4) identical to
primer 4 used to generate D2–9; D2–116 (DGag) (D2–
116), (1) identical to primer 1 used to generate D2–9, (2)
59-TTA ATT GCA GAA ACC GTC ATG GCC CGT GCT
CTG TGT CGT CCC-39, (3) 59-GGG ACG ACA CAG AGC
ACG GGC CAT GAC GGT TTC TGC AAT TAA-39, (4)
59-GGT GCC AGA TCT TCT CCA-39; G2AD9–18 (template
is pBluescript v-fgr G2A), (1) identical to primer 1 used to
generate D2–9, (2) 59-ACT ATA ACT ACC CCC TTA AGC
GCA CGG GCC CAT AAT CAA GGT-39, (3) 59-ACC TTG
ATT ATG GGC CCG TGC GCT TAA GGG GGT AGT TAT
AGT-39, (4) identical to primer 4 used to generate DGag;
G2AD19–38 (template is pBluescript v-fgr G2A), (1) iden-
tical to primer 1 used to generate DGag, (2) 59-GAT CAC
TGG TCT GAA GTC CGA GCC GAA TGG GTG ATG ATG
AAT-39, (3) 59-ATT CAT CAT CAC CCA TTC GGC TCG
GAC TTC AGA CCA GTG ATC-39, (4) identical to primer
4 used to generate DGag; G2AD39–58 (template is
pBluescript v-fgr G2A), (1) identical to primer 1 used to
generate DGag, (2) 59-AAA TGG ATT ACC TTA TGT GAG
ATT TCC CAG GTT GAA AAA AAG-39, (3) 59-CTT TTT TTC
AAC CTG GGA AAT CTC ACA TAA GGT AAT GGA
TTT-39, (4) identical to primer 4 used to generate DGag;
G2AD58–78 (template is pBluescript v-fgr G2A), (1) iden-
tical to primer 1 used to generate DGag, (2) 59-GGA ACT
TTT TCT CTT GAT AAC CCT TAC ATT ACC ACA TGG
AGA-39, (3) 59-TCT CCA TGT GGT AAT GTA AGG GTT
ATC AAG AGA AAA AGT TCC-39, (4) identical to primer
4 used to generate DGag; G2aD79–98 (template is
pBluescript v-fgr G2A), (1) identical to primer 1 used to
generate DGag, (2) 59-TAT GGA CAC CCC GAC CAA
GTT CTA CCC CCT CCC AAA CCT CCC-39, (3) 59-GGG
AGG TTT GGG AGG GGG TAG AAC TTG GTC GGG GTG
TCC ATA-39, (4) identical to primer 4 used to generate
DGag; G2aD99–116 (template is pBluescript v-fgr G2A),
(1) identical to primer 1 used to generate DGag, (2)
59-CCT TCG TGG GTT CGT CCG TTC GCC CGT GCT
CTG TGT CGT CCC-39, (3) 59-GGG ACG ACA CAG AGC
ACG GGC GAA CGG ACG AAC CCA CGA AGG-39, (4)
identical to primer 4 used to generate DGag; D10–116, (1)
same as primer 1 used to generate D2–9, (2) 59-ATA ACT
ACC CCC TTA AGC GCC CGT GCT CTG TGT CGT CCC-
39, (3) 59-GGG ACG ACA CAG AGC ACG GGC GCT TAA
GGG GGT AGT TAT AGT-39, (4) same as primer 4 used
to generate DGag; D3–116 (template is DGag), (1) same
as primer 1 used to generate DGag, (2) 59-ATT GCA GAA
ACC GTC ATG GGC GCC CGT GCT CTG TGT CGT CCC-
39, (3) 59-GGG ACG ACA CAG AGC ACG GGC GCC CAT
GAC GGT TTC TGC AAT-39, (4) identical to primer 4 used
to generate DGag; D79–116, (1) identical to primer 1 used
to generate DGag, (2) identical to primer 2 used to
generate D79–98, (3) identical to primer 3 used to gen-
erate D99–116, (4) identical to primer 4 used to generate
DGag; G2AD79–116, all primers are identical to those
used to generate D79–116 except that the template DNA
is pBluescript v-fgr G2A.
In vitro translation
Wild-type and mutant v-fgr cDNAs were subcloned into
the SacI and EcoRV sites of the pBluescript KS vector
(Stratagene). Qiagen purified plasmid DNA (1 mg) was
added to a T7-primed TNT coupled in vitro transcription/
translation kit (Promega) supplemented with 35S-express
protein labeling mix (NEN, DuPont) as a source of me-
thionine of 50 mCi or 3H-myristic acid (NEN, DuPont).
Reactions were performed at 30°C for 2 h, and a 5-ml
aliquot (for 35S-labeled proteins) or the entire reaction
mixture (for 3H-labeled proteins) analyzed by 10% SDS–
PAGE according to Lammeli (1970). The resulting gels
were fixed twice for 15 min each at room temperature in
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fixative solution (10% acetic acid/30% methanol), en-
hanced for 30 min at room temperature in enlightening
solution (NEN, DuPont), dried, and analyzed by autora-
diography (for 35S-labeled proteins) or by phosphorim-
ager analysis using a tritium-sensitive screen (Fuji) (for
3H-labeled proteins).
Subcellular fractionation of NIH-3T3 cells
NIH-3T3 cells were washed twice in STE (150 mM
NaCl; 50 mM Tris-Cl, pH 7.5; and 1 mM EDTA), collected
by low-speed centrifugation at 1000 g, and resuspended
in hypotonic buffer (10 mM Tris-Cl, pH 7.5, and 0.2 mM
MgCl2). Cells were dounce homogenized and the ho-
mogenate adjusted to a final concentration of 0.25 M
sucrose and 1 mM EDTA. Nuclei and heavier mem-
branes were pelleted at 1000 g, and the supernatant
further centrifuged at 100,000 g for 1 h. The pellet (con-
taining the cytoplasmic membrane fraction) was resus-
pended in NTE buffer (100 mM NaCl; 10 mM Tris-Cl, pH
7.5; and 1 mM EDTA) and dounce homogenized immedi-
ately prior to use in in vitro membrane association as-
says.
In vitro membrane association assays
All in vitro membrane association assays were per-
formed as previously described (Resh, 1989). NIH-3T3
cytoplasmic membrane fraction (15 mg) was combined
with 5 ml of in vitro translated v-Fgr protein (or NTE buffer
for a negative control) and adjusted with NTE buffer to a
final volume of 30 ml. Samples were incubated at 20°C
for 30 min and centrifuged at 150,000 g, and the pellet
(representing the amount of membrane bound protein)
and supernatant (representing the amount of unbound,
cytoplasmic protein) of each reaction were separately
analyzed by SDS–PAGE according to Lammeli (1970).
The resulting gels were fixed twice for 15 min each at
room temperature in fixative solution (10% acetic acid
and 30% methanol), enhanced for 30 min at room tem-
perature in enlightening solution (NEN, DuPont), dried,
and analyzed by autoradiography. Quantitation was per-
formed using MacBas software in conjunction with the
Fuji phosphorimager.
Generation of v-fgr NIH-3T3 clonal cell lines
NIH-3T3 cells were transfected using the calcium
phosphate method as previously described (Graham and
van der Eb, 1973) using v-fgr cDNAs that were subcloned
into the pMV7 retroviral vector (Kirchmeier et al., 1988).
Transfected cells were selected using 250 mg/ml of
G418, and these cells, representing the mass culture,
were diluted into 96-well microtiter plates at a density of
1 cell per well and allowed to grow. The kinase activity of
individual clones were determined using in vitro kinase
assays.
Soft agar anchorage-independent colony formation
assays
A 1% noble agar solution (4 ml) at 55°C was combined
with 9 ml of DMEM supplemented with 5% or 10% calf
serum and penicillin-streptomycin. Two milliliters of this
mixture was added to a 60-mm plate and allowed to
stand at room temperature for 30 min. NIH-3T3 v-fgr and
control cells (1 3 105) were adjusted to a final volume of
0.5 ml in the above media and combined with 2.5 ml of
noble agar/DMEM mixtures (1.3 ml DMEM and 0.8 ml of
1% noble agar). Anchorage-independent colonies were
scored 2 weeks after plating.
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